Immune responses to AAV vectors, from bench to bedside / / edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy.
The recent wave of clinical studies highlighted the enormous potential of gene therapy as an approach to the treatment of inherited disorders. While in recent years lentiviral vectors have dominated the field of ex vivo gene transfer applications in man, adeno-associated virus (AAV) vectors have bec...
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | [Lausanne, Switzerland] : : Frontiers Media SA,, 2015. |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 online resource (95 pages) :; illustrations. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547921904498 |
---|---|
ctrlnum |
(CKB)3710000000520096 (WaSeSS)IndRDA00058898 (oapen)https://directory.doabooks.org/handle/20.500.12854/49980 (EXLCZ)993710000000520096 |
collection |
bib_alma |
record_format |
marc |
spelling |
Hildegard Buning auth Immune responses to AAV vectors, from bench to bedside / edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy. Frontiers Media SA 2015 [Lausanne, Switzerland] : Frontiers Media SA, 2015. 1 online resource (95 pages) : illustrations. text txt rdacontent computer c rdamedia online resource cr rdacarrier text file rda Frontiers Research Topics Includes bibliographical references. The recent wave of clinical studies highlighted the enormous potential of gene therapy as an approach to the treatment of inherited disorders. While in recent years lentiviral vectors have dominated the field of ex vivo gene transfer applications in man, adeno-associated virus (AAV) vectors have become the platform of choice for the in vivo correction of many diseases. Despite these successes, however, studies in humans evidenced the immune system as one of the last few hurdles to be overcome in order to achieve sustained disease correction, particularly with AAV vectors. These observations spurred a decade of enormous efforts by gene therapists to understand the factors that contribute to the vector immunogenicity, including the prevalence of B cell and T cell immunity to wild type AAV in humans, and the interaction of AAV vectors with the innate immune system. Our knowledge is still rudimental. This is partly due to the fact that the basic knowledge on the complex balance between tolerance and immunity to an antigen keeps evolving rapidly. The lack of predictive animal models has also been a major limitation to the advancement of our understanding of vector immunogenicity, limiting studies to the use of specimens from human trials or in vitro models. Furthermore, immunomonitoring studies in AAV gene transfer trials were conducted by multiple laboratories and with different assays, making results comparison difficult.Continuing work towards a better definition of the interaction of viral vectors with the immune system, however, has led to significant advances in the knowledge of the factors influencing the outcome of gene transfer, such as the target tissue, the vector dose, and the induction of tolerance to an antigen. A better understanding of the structure function of the viral capsid has boosted the development of novel immune-escape vector variants, and novel immunomodulatory or immunosuppressive strategies to prevent, overcome or reduce anti-capsid immunity have been developed and tested in the preclinical and clinical settings. Together, these advances are bringing us closer to the goal of achieving safe and sustained therapeutic gene transfer in humans.In this exciting research topic, hosted by Frontiers in Immunology, we will highlight critical aspects in the bench-to-bedside cycle of development of AAV therapeutics as they relate with the issue of immunity to viral vectors. For this purpose, a collection of Original Research articles, Review Articles, and Methods Articles will discuss both our basic knowledge in immunology and AAV biology, and the preclinical and clinical experience with AAV vectors, including the tools used to decipher the complex interactions between a gene transfer vehicle and the host immune system. Description based on: online resource; title from pdf title page (frontiers, viewed Jul. 8, 2016). English Immunologic diseases. Gene therapy. antibody response Clinical Trial Gene Therapy Regulatory T Cell Immunomodulation Tolerance induction adaptive and innate immunity adeno-associated virus Vaccine Epitopes Mingozzi, Federico, editor. Büning, Hildegard, editor. Basner-Tschakarjan, Etiena, editor. Galy, Anne, editor. |
language |
English |
format |
Book Chapter |
author |
Hildegard Buning |
spellingShingle |
Hildegard Buning Immune responses to AAV vectors, from bench to bedside / Frontiers Research Topics |
author_facet |
Hildegard Buning Mingozzi, Federico, Büning, Hildegard, Basner-Tschakarjan, Etiena, Galy, Anne, |
author_variant |
h b hb |
author2 |
Mingozzi, Federico, Büning, Hildegard, Basner-Tschakarjan, Etiena, Galy, Anne, |
author2_variant |
f m fm h b hb e b t ebt a g ag |
author2_role |
TeilnehmendeR TeilnehmendeR TeilnehmendeR TeilnehmendeR |
author_sort |
Hildegard Buning |
title |
Immune responses to AAV vectors, from bench to bedside / |
title_full |
Immune responses to AAV vectors, from bench to bedside / edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy. |
title_fullStr |
Immune responses to AAV vectors, from bench to bedside / edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy. |
title_full_unstemmed |
Immune responses to AAV vectors, from bench to bedside / edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy. |
title_auth |
Immune responses to AAV vectors, from bench to bedside / |
title_new |
Immune responses to AAV vectors, from bench to bedside / |
title_sort |
immune responses to aav vectors, from bench to bedside / |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2015 |
physical |
1 online resource (95 pages) : illustrations. |
isbn |
9782889195008 (ebook) |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC582 |
callnumber-sort |
RC 3582 |
illustrated |
Illustrated |
work_keys_str_mv |
AT hildegardbuning immuneresponsestoaavvectorsfrombenchtobedside AT mingozzifederico immuneresponsestoaavvectorsfrombenchtobedside AT buninghildegard immuneresponsestoaavvectorsfrombenchtobedside AT basnertschakarjanetiena immuneresponsestoaavvectorsfrombenchtobedside AT galyanne immuneresponsestoaavvectorsfrombenchtobedside |
status_str |
n |
ids_txt_mv |
(CKB)3710000000520096 (WaSeSS)IndRDA00058898 (oapen)https://directory.doabooks.org/handle/20.500.12854/49980 (EXLCZ)993710000000520096 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Immune responses to AAV vectors, from bench to bedside / |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1787548435211091968 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04638naa a2200529 i 4500</leader><controlfield tag="001">993547921904498</controlfield><controlfield tag="005">20230621140359.0</controlfield><controlfield tag="006">m o u </controlfield><controlfield tag="007">cr#|||||||||||</controlfield><controlfield tag="008">160708s2015 sz a o 000|u eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9782889195008 (ebook)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000520096</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00058898</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49980</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000520096</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">WaSeSS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">WaSeSS</subfield><subfield code="d">UkMaJRU</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC582</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hildegard Buning</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Immune responses to AAV vectors, from bench to bedside /</subfield><subfield code="c">edited by Federico Mingozzi, Hildegard Büning, Etiena Basner-Tschakarjan and Anne Galy.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (95 pages) :</subfield><subfield code="b">illustrations.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The recent wave of clinical studies highlighted the enormous potential of gene therapy as an approach to the treatment of inherited disorders. While in recent years lentiviral vectors have dominated the field of ex vivo gene transfer applications in man, adeno-associated virus (AAV) vectors have become the platform of choice for the in vivo correction of many diseases. Despite these successes, however, studies in humans evidenced the immune system as one of the last few hurdles to be overcome in order to achieve sustained disease correction, particularly with AAV vectors. These observations spurred a decade of enormous efforts by gene therapists to understand the factors that contribute to the vector immunogenicity, including the prevalence of B cell and T cell immunity to wild type AAV in humans, and the interaction of AAV vectors with the innate immune system. Our knowledge is still rudimental. This is partly due to the fact that the basic knowledge on the complex balance between tolerance and immunity to an antigen keeps evolving rapidly. The lack of predictive animal models has also been a major limitation to the advancement of our understanding of vector immunogenicity, limiting studies to the use of specimens from human trials or in vitro models. Furthermore, immunomonitoring studies in AAV gene transfer trials were conducted by multiple laboratories and with different assays, making results comparison difficult.Continuing work towards a better definition of the interaction of viral vectors with the immune system, however, has led to significant advances in the knowledge of the factors influencing the outcome of gene transfer, such as the target tissue, the vector dose, and the induction of tolerance to an antigen. A better understanding of the structure function of the viral capsid has boosted the development of novel immune-escape vector variants, and novel immunomodulatory or immunosuppressive strategies to prevent, overcome or reduce anti-capsid immunity have been developed and tested in the preclinical and clinical settings. Together, these advances are bringing us closer to the goal of achieving safe and sustained therapeutic gene transfer in humans.In this exciting research topic, hosted by Frontiers in Immunology, we will highlight critical aspects in the bench-to-bedside cycle of development of AAV therapeutics as they relate with the issue of immunity to viral vectors. For this purpose, a collection of Original Research articles, Review Articles, and Methods Articles will discuss both our basic knowledge in immunology and AAV biology, and the preclinical and clinical experience with AAV vectors, including the tools used to decipher the complex interactions between a gene transfer vehicle and the host immune system.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from pdf title page (frontiers, viewed Jul. 8, 2016).</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Immunologic diseases.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Gene therapy.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Clinical Trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gene Therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Regulatory T Cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunomodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Tolerance induction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptive and innate immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adeno-associated virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Epitopes</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mingozzi, Federico,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Büning, Hildegard,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Basner-Tschakarjan, Etiena,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Galy, Anne,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-06-25 12:48:41 Europe/Vienna</subfield><subfield code="d">00</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-12-12 16:57:58 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338709130004498&Force_direct=true</subfield><subfield code="Z">5338709130004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338709130004498</subfield></datafield></record></collection> |